Overweight ISRG via staged 20% initial tranche with $346 risk floor and $450 target on 12-18 month horizon
Overweight ISRG with staged entry; initiate ~20% of target at $370-$375, reserve balance for confirmation on retest or breakout. $450 target valid if fundamentals hold and technical repair occurs; invalidate on $346 risk breach, $329 sustained close below, $300 regime change, or Q3 2026 earnings without reacceleration above 15% US procedure growth.
| Position | Action |
|---|---|
| Initial tranche at ~$370-$375 | Size at ~20% of target allocation |
| Higher low on $346-$360 retest OR volume-confirmed close above $387.51 50-day SMA and $402 with positive MACD and RSI >55 | Add next tranche |
| Q3 2026 print without US procedure growth reaccelerating above 15% and stronger system placements | Trim position |
| Confirmed reacceleration with US procedure growth above 15% | Complete Overweight allocation |
High-quality compounder being thrown out with bearish bathwater; Q2 2026 fundamentals accelerating while technicals signal generational contrarian buy signal at multi-year valuation discount.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 45.23 | neutral |
| MACD | 0.49 | bearish |
| MACD Histogram | -0.01 | bearish |
| 50 SMA | $387.51 | bearish |
| 200 SMA | $472.32 | bearish |
| 10 EMA | $383.53 | bearish |
| Bollinger Upper Band | $412.22 | neutral |
| Bollinger Middle Band | $379.52 | bearish |
| Bollinger Lower Band | $346.82 | neutral |
| ATR (14) | 12.91 | neutral |
Support: 346.82 · 328.57 | Resistance: 383.53 · 387.51 · 401 · 404 · 412.22 · 472.32
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $346-$360 retest producing higher low
Then: Add tranche
Q2 2026 was the strongest quarter in a year, contradicting demand-softening thesis
↩ rebuts: “Bear's demand-softening narrative; GLP-1 structural headwind thesis”
EV: +26% (200 SMA reclaim to $472) · concedes: GLP-1s will reduce some bariatric procedure volume over time — the premise is conceded, but the magnitude is overstated by the bear relative to total procedure mix and TAM runway; Hospital capex constraint is real in the short term but cyclical, not structural — hospitals delay but don't cancel robotic surgery investments; Death cross (50 SMA below 200 SMA) is technically bearish in the near term — accepted as a valid short-term tape read; Near-term technicals are unambiguously bearish — the bear's technical observations are accurate
ISRG is a great company but at the wrong price—at 30.95x forward earnings with decelerating growth, structural GLP-1 headwinds, hospital capex pressure, multiple compression risk, and no Fed easing catalyst, the stock faces asymmetric downside that makes holding or selling the disciplined choice over buying.
EV: -25-40% · concedes: ISRG has a near-monopoly today (conceded); da Vinci 5 is promising but still in early commercial ramp (not invalidated); Q2'26 revenue print was good (conceded); Net cash position is genuinely impressive (conceded); Buyback program is consistent (conceded)
→ vs conservative: Waiting for ISRG to close above $402 before buying treats a fundamental value play as a momentum trade; they're asking us to wait for an 8% rally in a business with $5.2B net cash, zero debt, and accelerating growth, which is paralysis dressed up as prudence
→ vs conservative: The technical case is weaker than stated—MACD histogram at minus 0.01 shows no collapse, RSI at 45 is neutral, and declining volume into lows indicates classic late-stage selling exhaustion, not active distribution
→ vs neutral: Operating margin expanding for three consecutive years and Q2 revenue growing 18.5% year-over-year are clear secular positive signals, not 'mixed' data—the data actually strongly supports a bullish directional read
→ vs neutral: Framing GLP-1 as a structural demand substitute is the weakest argument leg; bariatric procedures are a subset of total robotic surgery volume, not the core driver, and the neutral analyst is treating a cyclical hiccup as a secular thesis-breaker
ISRG is in a deep, prolonged downtrend with price at $373.57 (2026-08-24), approximately 20.9% below the 200 SMA ($472.32) and 3.6% below the 50 SMA ($387.51). The stock declined roughly 44.8% from its January 7 high of $594.62 to the July 23 low of $328.57. An August bounce attempt stalled at $401.27, and momentum has rolled over — RSI at 45.23, MACD near zero at 0.49 with histogram turned negative at -0.01. Key support sits at $346.82 (lower Bollinger Band) and $328.57 (July low), while resistance is layered at $387.51 (50 SMA), $401-$404, $412.22 (upper BB), and $472.32 (200 SMA). A defensive posture is warranted until price reclaims the 50 SMA on sustained volume.
Market Cap
$133.84B
Share Price
~$378
52-Week Range
$328.57–$603.88
PE (TTM)
42.89x
Forward PE
30.95x
Forward EPS
$12.07
PEG Ratio
1.86
Price/Book
7.28x
Beta
1.46
50d Moving Avg
$388.30
200d Moving Avg
$473.15
Revenue (TTM)
$11,034M
Revenue FY2025
$10,065M
Revenue FY2024
$8,352M
Revenue FY2023
$7,124M
Revenue FY2022
$6,222M
Revenue Growth 3-Yr CAGR
17.4%
Revenue FY25 YoY
+20.5%
Q2'26 Revenue YoY
+18.5%
Gross Profit FY2025
$6,642M
Operating Income FY2025
$2,946M
EBITDA FY2025
$3,623M
EBITDA TTM
$4,181M
Net Income FY2025
$2,856M
Net Income TTM
$3,139M
Diluted EPS FY2025
$7.87
Diluted EPS TTM
$8.71
EPS Growth 3-Yr CAGR
29.3%
Gross Margin TTM
66.7%
Operating Margin TTM
33.6%
Net Margin TTM
28.4%
Gross Margin FY2025
66.0%
Operating Margin FY2025
29.3%
Net Margin FY2025
28.4%
Q2'26 Revenue
$2,892M
Q2'26 Gross Profit
$1,960M
Q2'26 Operating Income
$972M
Q2'26 Net Income
$818M
Q2'26 Diluted EPS
$2.29
ROE TTM
17.4%
ROA TTM
10.5%
FCF Margin TTM
~23.7%
Total Assets Q2'26
$20,877M
Cash & ST Investments Q2'26
$5,216M
Total Current Assets Q2'26
$9,543M
Total Non-Current Assets Q2'26
$11,334M
Total Liabilities Q2'26
$2,579M
Total Current Liabilities Q2'26
$1,923M
Long-Term Liabilities Q2'26
$656M
Stockholders' Equity Q2'26
$18,168M
Current Ratio Q2'26
4.96
Working Capital Q2'26
$7,620M
Inventory Q2'26
$2,029M
Goodwill Q2'26
$580.6M
Total Debt
~$0
Operating Cash Flow TTM
~$3,375M
CapEx TTM
~$485M
Free Cash Flow TTM
$2,615M
Free Cash Flow FY2025
$2,491M
Free Cash Flow FY2024
$1,304M
Stock Repurchases FY2025
$2,295M
Stock Repurchases H1'26
$1,44B
Diluted Shares Q2'26
357.3M
Diluted Shares Q2'25
364M
R&D Q2'26
$370.6M
SG&A Q2'26
$617.9M
Effective Tax Rate Q2'26
21.9%
Effective Tax Rate FY2025
13.1%
Strengths
Concerns
ISRG is the dominant global pioneer in robotic-assisted minimally invasive surgery through its da Vinci platform, exhibiting high-quality compounding characteristics: 17.4% 3-year revenue CAGR, 29.3% 3-year EPS CAGR, and expanding margins (operating margin 25.3% → 29.3%). The Q2'26 quarter showed acceleration with 18.5% YoY revenue growth and EPS of $2.29. The balance sheet is fortress-like with $5.2B net cash, zero debt, and a 4.96x current ratio, while free cash flow generation is elite (~$2.6B TTM, ~24% FCF margin). Management returned $2.3B via buybacks in FY2025 and $1.44B in H1'26, reducing share count ~2% annually. Key risks include full valuation (42.89x PE), negative technical trend, a normalized effective tax rate of 21.9% versus 13.1% in FY2025, and rising inventory that warrants monitoring in subsequent quarters.
Macro: Fed rate path: Polymarket assigns 86% probability to zero Fed rate cuts in 2026 (up approximately 1.2 percentage points week-over-week on $7.5M volume), indicating higher-for-longer environment. US recession probability by end of 2026 is 8% on $1.7M volume — very low, supportive of hospital capex and elective procedures. Japan recession probability is 22% (down sharply 33.5 percentage points week-over-week), signaling improving global outlook. Commodities: Gold at $4,640.80 (+0.36%); silver up over 18% month-over-month, suggesting broad safe-haven demand. FRED macro data was unavailable for this session (CPI, Fed Funds Rate, 10Y Treasury, Unemployment, VIX, and 10Y-2Y spread all returned DATA_UNAVAILABLE).